dipyridamole has been researched along with Restless Legs Syndrome in 2 studies
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.
Restless Legs Syndrome: A disorder characterized by aching or burning sensations in the lower and rarely the upper extremities that occur prior to sleep or may awaken the patient from sleep.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A 2-week double-blind, placebo-controlled crossover study assessed the efficacy of dipyridamole (possible up-titration to 300 mg) in untreated patients with idiopathic restless legs syndrome." | 9.41 | A Randomized, Placebo-Controlled Crossover Study with Dipyridamole for Restless Legs Syndrome. ( Ferré, S; Garcia-Borreguero, D; Garcia-Malo, C; Granizo, JJ, 2021) |
| "Dipyridamole was generally well tolerated." | 6.87 | Treatment of restless legs syndrome/Willis-Ekbom disease with the non-selective ENT1/ENT2 inhibitor dipyridamole: testing the adenosine hypothesis. ( Cano-Pumarega, I; Ferré, S; Garcia Malo, C; Garcia-Borreguero, D; Granizo, JJ; Guitart, X, 2018) |
| "A 2-week double-blind, placebo-controlled crossover study assessed the efficacy of dipyridamole (possible up-titration to 300 mg) in untreated patients with idiopathic restless legs syndrome." | 5.41 | A Randomized, Placebo-Controlled Crossover Study with Dipyridamole for Restless Legs Syndrome. ( Ferré, S; Garcia-Borreguero, D; Garcia-Malo, C; Granizo, JJ, 2021) |
| "Dipyridamole was generally well tolerated." | 2.87 | Treatment of restless legs syndrome/Willis-Ekbom disease with the non-selective ENT1/ENT2 inhibitor dipyridamole: testing the adenosine hypothesis. ( Cano-Pumarega, I; Ferré, S; Garcia Malo, C; Garcia-Borreguero, D; Granizo, JJ; Guitart, X, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Garcia-Borreguero, D | 2 |
| Garcia-Malo, C | 1 |
| Granizo, JJ | 2 |
| Ferré, S | 2 |
| Guitart, X | 1 |
| Garcia Malo, C | 1 |
| Cano-Pumarega, I | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effect of Magnesium Citrate Supplementation in Patients With Restless Legs Syndrome (RLS) - An Open Label, Prospective, Non Placebo Controlled Pilot Study[NCT04462796] | 15 participants (Anticipated) | Interventional | 2020-07-10 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for dipyridamole and Restless Legs Syndrome
| Article | Year |
|---|---|
A Randomized, Placebo-Controlled Crossover Study with Dipyridamole for Restless Legs Syndrome.
Topics: Cross-Over Studies; Dipyridamole; Dopamine Agonists; Double-Blind Method; Humans; Polysomnography; R | 2021 |
Treatment of restless legs syndrome/Willis-Ekbom disease with the non-selective ENT1/ENT2 inhibitor dipyridamole: testing the adenosine hypothesis.
Topics: Adenosine; Dipyridamole; Female; Humans; Male; Middle Aged; Phosphodiesterase Inhibitors; Polysomnog | 2018 |